Nivalis Therapeutics

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.
Boulder, US
Size (employees)
29 (est)
Nivalis Therapeutics was founded in 2007 and is headquartered in Boulder, US

Nivalis Therapeutics Office Locations

Nivalis Therapeutics has office in Boulder
Boulder, US

Nivalis Therapeutics Metrics

Nivalis Therapeutics Summary

Market capitalization

$44.2 m

Closing share price

Nivalis Therapeutics's current market capitalization is $44.2 m.

Nivalis Therapeutics Market Value History

Nivalis Therapeutics Online Presence

Nivalis Therapeutics Company Life

You may also be interested in